Cell Source Stock-Based Compensation Growth & History (CLCS)
Cell Source's stock-based compensation was $288,424 for fiscal 2024.
View full Cell Source company overviewCell Source annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | $288,424 | −$174,610 | −37.71% |
| 2023 | 2023-12-31 | $463,034 | $385,147 | +494.49% |
| 2022 | 2022-12-31 | $77,887 | −$341,514 | −81.43% |
| 2021 | 2021-12-31 | $419,401 | −$372,267 | −47.02% |
| 2020 | 2020-12-31 | $791,668 | −$52,460 | −6.21% |
| 2019 | 2019-12-31 | $844,128 | $866,628 | — |
| 2018 | 2018-12-31 | −$22,500 | −$67,219 | — |
| 2017 | 2017-12-31 | $44,719 | −$70,040 | −61.03% |
| 2016 | 2016-12-31 | $114,759 | −$21,125 | −15.55% |
| 2015 | 2015-12-31 | $135,884 | −$765,416 | −84.92% |
| 2014 | 2014-12-31 | $901,300 | $901,300 | — |
| 2013 | 2013-12-31 | $0 | — | — |
Cell Source quarterly stock-based compensation
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q1 2025 | 2025-03-31 | $104,475 | −$184,420 | −63.84% |
| Q4 2024 | 2024-12-31 | −$20,873 | −$78,929 | — |
| Q3 2024 | 2024-09-30 | $5,070 | −$20,892 | −80.47% |
| Q2 2024 | 2024-06-30 | $15,332 | −$34,779 | −69.40% |
| Q1 2024 | 2024-03-31 | $288,895 | −$40,010 | −12.16% |
| Q4 2023 | 2023-12-31 | $58,056 | — | — |
| Q3 2023 | 2023-09-30 | $25,962 | −$48,794 | −65.27% |
| Q2 2023 | 2023-06-30 | $50,111 | $50,037 | +67617.57% |
| Q1 2023 | 2023-03-31 | $328,905 | $323,945 | +6531.15% |
| Q3 2022 | 2022-09-30 | $74,756 | −$65,772 | −46.80% |
| Q2 2022 | 2022-06-30 | $74 | −$45,898 | −99.84% |
| Q1 2022 | 2022-03-31 | $4,960 | −$232,812 | −97.91% |
| Q3 2021 | 2021-09-30 | $140,528 | −$208,522 | −59.74% |
| Q2 2021 | 2021-06-30 | $45,972 | −$286,922 | −86.19% |
| Q1 2021 | 2021-03-31 | $237,772 | $0 | 0.00% |
| Q3 2020 | 2020-09-30 | $349,050 | $347,300 | +19845.71% |
| Q2 2020 | 2020-06-30 | $332,894 | — | — |
| Q1 2020 | 2020-03-31 | $237,772 | — | — |
| Q3 2019 | 2019-09-30 | $1,750 | — | — |
| Q4 2017 | 2017-12-31 | $85 | — | — |
| Q3 2017 | 2017-09-30 | $351 | −$23,276 | −98.51% |
| Q2 2017 | 2017-06-30 | $20,780 | −$2,312 | −10.01% |
| Q1 2017 | 2017-03-31 | $23,503 | −$45,367 | −65.87% |
| Q3 2016 | 2016-09-30 | $23,627 | −$66,532 | −73.79% |
| Q2 2016 | 2016-06-30 | $23,092 | $46,592 | — |
| Q1 2016 | 2016-03-31 | $68,870 | $78,770 | — |
| Q4 2015 | 2015-12-31 | $79,125 | −$779,175 | −90.78% |
| Q3 2015 | 2015-09-30 | $90,159 | $90,159 | — |
| Q2 2015 | 2015-06-30 | −$23,500 | −$66,500 | — |
| Q1 2015 | 2015-03-31 | −$9,900 | −$9,900 | — |
| Q4 2014 | 2014-12-31 | $858,300 | — | — |
| Q3 2014 | 2014-09-30 | $0 | $0 | — |
| Q2 2014 | 2014-06-30 | $43,000 | — | — |
| Q1 2014 | 2014-03-31 | $0 | — | — |
| Q3 2013 | 2013-09-30 | $0 | — | — |
Cell Source stock-based compensation trends
Over the last five fiscal years, Cell Source's stock-based compensation decreased from $844,128 to $288,424, a change of −$555,704. The latest reported quarter, Q1 2025, shows $104,475.
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cell Source source filings ↗